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Abstract
Background: Resection of the bile duct is required for the treatment of cholangiocarcinoma and is
sometimes indicated in resections of liver and gallbladder malignancies. The goal of this retrospective
review was to characterize surgical outcomes in patients submitted to bile duct resection for malig-
nancy when additional procedures, specifically hepatic or vascular resections, were performed.
Methods: The American College of Surgeons National Surgical Quality Improvement Program data-
base was searched to identify a total of 747 patients who underwent: (i) biliary-enteric anastomosis
(BEA) only (Group 1, n = 266); (ii) BEA with hepatic resection (Group 2, n = 439), or (iii) BEA with
hepatic and vascular resection (Group 3, n = 42). Postoperative outcomes were compared and regres-
sion-adjusted risk factors were analysed to produce observed and expected (O/E) morbidity and
mortality ratios.
Results: The performance of hepatic and vascular resections significantly increased rates of overall
morbidity (P < 0.001) and mortality (P = 0.021). Risk-adjusted O/E mortality ratios in Groups 1, 2 and 3
were 1.44 [95% confidence interval (CI) 0.84–2.30], 2.16 (95% CI 1.51–2.98) and 5.92 (95% CI 2.54–
11.66), respectively. Multivariate analysis identified Group 2 (P < 0.001) and Group 3 (P = 0.001) status
as independent predictors of morbidity, and Group 3 status (P = 0.008) as independently associated
with mortality. More than 30% of deaths were associated with pulmonary complications and septic
shock.
Conclusions: The addition of hepatic and vascular resections to bile duct resection significantly
increased morbidity and mortality. The high O/E mortality ratios for patients in Groups 2 and 3 suggest
these outcomes can be improved.
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Introduction
The surgical treatment of biliary and gallbladder malignancies
continues to evolve as more extensive procedures are
performed in efforts to provide complete tumour extirpation
with negative margins and promote longterm survival or
potential cure. In the case of hilar cholangiocarcinoma, bile
duct resection is required for treatment, but the addition of
hepatic resection has been shown to improve oncologic out-
comes with reasonable rates of morbidity and mortality.1–5
More recently, various authors have reported the use of
vascular resection in the treatment of cholangiocarcinoma and
gallbladder malignancy with mixed results.6–12 Vascular resec-
tion is usually carried out when the primary tumour has
invaded the portal vein and/or hepatic artery, necessitating the
resection and reconstruction of these structures in order to
obtain a negative-margin (R0) resection. These reports derive
This study was presented as a long oral presentation at the Annual
Meeting of the AHPBA, 11–15 March 2015, Miami, Florida.
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from specialized units and surgeons with expertise in the man-
agement of the reported malignancies and describe both peri-
operative outcomes and longterm overall survival. With the
exception of one report,11 information is limited to single-in-
stitution studies with small sample sizes and is subject to biases
associated with the reporting institution. In addition, there
have been several recent meta-analyses of the outcomes of
vascular resection in hilar cholangiocarcinoma.13–15 As a group,
these studies show vascular resection to be a feasible operative
strategy, but some have reported postoperative outcomes simi-
lar to those of less extensive procedures, whereas others have
shown increased mortality.
The aims of this study were to examine clinical outcomes
in patients undergoing biliary surgery for hepatobiliary and
gallbladder malignancies and to determine the effects of addi-
tional procedures such as hepatic and vascular resection on
postoperative outcomes using data from the American College
of Surgeons (ACS) National Surgical Quality Improvement
Program (NSQIP).16 Unlike data derived from specialized
hepatobiliary centres, the NSQIP database represents out-
comes from a variety of hospital settings with varying levels
of volume and expertise and thus its data are more represen-
tative of actual practice across the USA. In addition, the
results are risk-adjusted based on preoperative clinical infor-
mation to facilitate the calculation of expected rates of mor-
bidity and mortality. The secondary aim of this study was to
identify independent risk factors for increased morbidity and
mortality in patients undergoing bile duct resection and
reconstruction with or without hepatic or vascular resection.
It was hypothesized that hepatic and vascular procedures
combined with bile duct reconstruction will increase the post-
operative incidences of morbidity and mortality associated
with surgery for biliary and gallbladder malignancies. This
study sought to quantify the decrement in outcomes in a
large population-based dataset and to determine if these out-
comes can be improved.
Materials and methods
This study was approved by the Wake Forest University Health
Sciences Institutional Review Board and the Protocol Review
Committee of the Comprehensive Cancer Center of Wake
Forest University.
Data source
The ACS NSQIP is a data-driven, risk-adjusted, outcomes-
based programme designed to measure and improve the qual-
ity of surgical care.16 Details regarding sampling strategy, data
collection protocol, the variables collected and organization
have been previously reported.17 This study uses the 2005–
2012 Participant Use Files (PUF), which contain 295 Health
Insurance Portability and Accountability Act (HIPAA) com-
plaint variables on 543 885 surgical patients.
Study design
Patients older than 16 years of age were identified using Current
Procedural Terminology (CPT) codes for biliary-enteric anasto-
mosis (BEA), hepatic resection and vascular resection
(Appendix S1, online). The codes were then correlated with
International Classification of Diseases, Ninth Revision (ICD-9)
codes for biliary and gallbladder malignancies (Appendix S1).
Patients were then grouped into three categories based on their
CPT codes according to whether they underwent BEA only
(Group 1), BEA with hepatic resection (Group 2), or BEA with
hepatic and vascular resection (Group 3). All patients in these
three groups had a diagnosis equivalent to one of the ICD-9
codes described above.
In order to reduce confounding and create a study popula-
tion that represented the inherent risks associated with the
procedures specifically selected based on CPT codes for this
study, patients with CPT codes that referred to major surgical
procedures other than those covered in the present three pro-
cedure groups were excluded (n = 40). These included patients
submitted to partial gastrectomy, partial colectomy or pancrea-
tectomy.
Primary endpoints for this study were 30-day postoperative
mortality rates, overall morbidity rates, and specific complica-
tion rates stratified by the type of procedure performed. Speci-
fic complications analysed included: cardiac arrest requiring
cardiopulmonary resuscitation (CPR); deep incisional surgical
site infection (SSI); organ space SSI; sepsis or septic shock;
unplanned intubation; mechanical ventilation for >48 h; pneu-
monia; acute renal failure; progressive renal insufficiency; deep
vein thrombosis (DVT); pulmonary embolus; any need for
return to the operating room; superficial SSI, and urinary tract
infection. Definitions of complications are based on the NSQIP
Operations Manual.17 Other covariates of interest included age,
body mass index (BMI), sex, race, American Society of Anes-
thesiologists (ASA) physical status class,18 smoking status (cur-
rent smoker within 1 year), comorbidities (diabetes mellitus,
ascites), recent weight loss (>10% of body weight in the
6 months prior to surgery), preoperative laboratory values
(serum albumin and total bilirubin), and functional status
(independent, partially dependent, totally dependent, unknown).
Statistical analysis
Demographic, preoperative and surgical characteristics were
compared by surgical procedure group using analyses of vari-
ance (ANOVAs), chi-squared tests and Fisher’s exact tests. All
additional analyses were then stratified by surgical procedure.
Observed and expected (O/E) morbidity and mortality ratios
using validated risk-adjustment models were calculated for the
overall group and by surgical procedure.19 Observed and
expected ratios were calculated using the mortality and
morbidity observed, and the expected probabilities of mortality
and morbidity for each patient. The expected probabilities of
mortality and morbidity are included in the NSQIP database
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and are determined ‘for all surgical patients based on a hierar-
chical regression analysis using the patient’s preoperative char-
acteristics as the independent or predictive variables’.17 To
predict whether each patient would experience an event,
sampling from a Bernoulli distribution using the NSQIP
probability was performed. The predicted events for the entire
sample were summed to obtain an expected number of events.
This process was repeated 500 times. The final expected event
rate was calculated using the mean of the 500 sampled
expected number of events.17 Univariate and multivariate logis-
tic regression models were used to assess the relationships
between covariates of interest and mortality and morbidity,
controlling for variables that were statistically significant and
clinically relevant. Additionally, a backward elimination model
strategy was used to determine which surgical complications
were associated with mortality in the multivariate model. The
criterion to be met in order to remain in the model was a
value of 0.2 and P-values of <0.05 were considered to indicate
statistical significance. All analyses were performed using SAS
Version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Demographics
A total of 747 patients who met the CPT code criteria and had
ICD-9 diagnoses of hepatobiliary or gallbladder malignancies
were identified in the 2012 NSQIP PUF. These included 266
(35.6%) patients who underwent BEA only (Group 1), 439
(58.8%) patients who underwent BEA and hepatic resection
(Group 2), and 42 (5.6%) patients who underwent BEA,
hepatic resection and vascular resection (Group 3). Table 1
presents demographic and preoperative data for the study
cohort stratified by procedure. One hundred sixty-three
patients in this study cohort did not have race identified.
Therefore the denominator for each column of Table 1 under
ethnicity is 584, 341, 208, and 35, respectively. Significant
P-values indicate a difference across all groups.
Morbidity
The overall morbidity rate was 53.8%. Complications signifi-
cantly increased in the unadjusted setting as hepatic and vascu-
lar resections were performed in conjunction with bile duct
resection (Table 1).
Predictors of morbidity for the entire study cohort are
shown in Table 2. Risk-adjusted O/E ratios for morbidity and
mortality by group are shown in Table 3.
Mortality
The overall mortality rate was 8.2%. Rates of 30-day mortality
were 6.4%, 8.2% and 19.1% in Groups 1, 2 and 3, respectively
(P = 0.021).
In Group 1, there were 17 deaths and the most commonly
associated complications were re-intubation (n = 7), mechani-
cal ventilation for >48 h (n = 6) and septic shock (n = 5).
Similarly, in Group 2, there were 36 deaths and the most com-
monly associated complications were re-intubation (n = 21),
mechanical ventilation for >48 h (n = 19) and septic shock
(n = 20). In Group 3, there were eight deaths and the most
commonly associated complications were mechanical ventila-
tion for >48 h (n = 3) and acute renal failure (n = 3).
Predictors of mortality for the entire study cohort are shown
in Table 4.
Discussion
Bile duct resection is a required component in the surgical
treatment of cholangiocarcinoma; however, it may also be per-
formed as part of the management of certain hepatic and gall-
bladder neoplasms depending on the clinical presentation. The
focus of this analysis was to determine the effects of hepatic
and vascular resections in addition to bile duct resection for
hepatobiliary and gallbladder malignancies. Given the nature of
the procedures examined and the selection criteria used, the
vast majority of these tumours were most likely those of hilar
cholangiocarcinoma and much of the discussion will focus on
the outcomes of surgical treatment for this disease. Although
the ICD-9 codes used also specify primary liver cancer and
gallbladder malignancies, the use of specific CPT codes starting
with BEA was selected to distinguish any malignancy with
extrahepatic biliary involvement that may have been included
in these diagnosis groupings.
Over the last two decades, several studies have demonstrated
improved survival in patients with hilar cholangiocarcinoma
treated with bile duct resection and major hepatic resection as
a result of increased R0 resection rates.1–5 A recent analysis
of hilar cholangiocarcinoma resected with combined major
hepatic resection demonstrated a positive correlation with the
tumour-free resection margin rate.20 Reported rates of postop-
erative morbidity and mortality ranged from 6% to 52% and
from 2% to 12%, respectively.20–26 In addition, a large popula-
tion-based analysis examined national trends in the manage-
ment of gallbladder carcinoma and found radical resection
with hepatectomy to be associated with improved survival on
multivariate analysis.27
The literature is unclear with respect to postoperative out-
comes associated with bile duct resection combined with both
hepatic and vascular resection for hilar cholangiocarcinoma. A
recent multi-institution analysis of 305 patients with hilar
cholangiocarcinoma examined the impact of portal vein resec-
tion on outcomes.11 In this group, 51 patients (16.7%) under-
went combined bile duct resection, hepatectomy and vascular
resection. The incidence of 90-day mortality in patients under-
going bile duct resection alone was lower (1.2%) than that in
patients submitted to bile duct resection with hepatic resection
(10.6%), and bile duct resection with hepatic and vascular
resection (17.6%) (P < 0.001). A meta-analysis by Abbas and
Sandroussi reviewed the role of vascular resection in the
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Table 1 Demographic, preoperative and postoperative data for patients submitted to biliary-enteric anastomosis (BEA) with and without
hepatic or vascular resection
Characteristic All patients
(n = 747)
BEA only
(n = 266)
BEA with
hepatic
resection
(n = 439)
BEA with
hepatic and
vascular
resection
(n = 42)
P-value
Preoperative characteristics
Age, years, median (range) 67 (20–89) 68 (33–89) 66 (20–86) 63 (33–82) <0.001
BMI, kg/m2, median (range) 26 (11–54) 26 (11–54) 26 (11–52) 25 (18–42) 0.538
Male sex, n (%) 433 (58%) 162 (61%) 244 (56%) 27 (64%) 0.210
White ethnicity, n (%) 446/584 (76%) 161/208 (77%) 256/341 (75%) 29/35 (83%) 0.533
ASA class 3 or 4, n (%) 557 (75%) 201 (76%) 325 (74%) 31 (74%) 0.897
DM with oral agents or insulin, n (%) 134 (18%) 58 (22%) 73 (17%) 3 (7%) 0.038
Current smoking, n (%) 124 (17%) 43 (16%) 71 (16%) 10 (24%) 0.434
Loss of >10% of body weight in last 6
months, n (%)
113 (15%) 45 (17%) 63 (14%) 5 (12%) 0.546
Independent functional health status prior
to surgery, n (%)
723 (97%) 251 (94%) 430 (98%) 42 (100%) 0.016
Ascites, n (%) 22 (3%) 8 (3%) 11 (3%) 3 (7%) 0.236
Preoperative serum albumin, g/dl,
median (range)
4 (2–7) 3 (2–5) 4 (2–7) 4 (2–5) <0.001
Preoperative total bilirubin, mg/dl,
median (range)
1 (0–15) 2 (0–15) 1 (0–15) 2 (0–9) 0.036
Chemotherapy for malignancy within
30 days preoperatively, n (%)
11 (2%) 4 (2%) 7 (2%) 0 0.766
Radiotherapy for malignancy in last
90 days, n (%)
6 (1%) 4 (2%) 2 (1%) 0 0.326
Postoperative data
Total operation time, min, median (range) 362 (11–1053) 294 (11–864) 394 (111–1053) 486 (249–803) <0.001
Length of total hospital stay, days,
median (range)
9 (0–94) 9 (2–62) 9 (0–94) 12 (1–42) 0.171
Return to operating room, n (%) 75 (10%) 20 (8%) 47 (11%) 8 (19%) 0.053
Superficial SSI, n (%) 78 (10%) 32 (12%) 44 (10%) 2 (5%) 0.325
Deep incisional SSI, n (%) 24 (3%) 8 (3%) 16 (4%) 0 0.4289
Organ space SSI, n (%) 134 (18%) 24 (9%) 99 (23%) 11 (26%) <0.001
Pneumonia, n (%) 43 (6%) 13 (5%) 26 (6%) 4 (10%) 0.474
Unplanned intubation, n (%) 62 (8%) 16 (6%) 43 (10%) 3 (7%) 0.203
Pulmonary embolism, n (%) 10 (1%) 2 (1%) 8 (2%) 0 0.360
On ventilator for >48 h, n (%) 63 (8%) 14 (5%) 43 (10%) 6 (14%) 0.041
Progressive renal insufficiency, n (%) 21 (3%) 8 (3%) 12 (3%) 1 (2%) 0.963
Acute renal failure, n (%) 19 (3%) 1 (0.4%) 15 (3%) 3 (7%) 0.007
Urinary tract infection, n (%) 30 (4%) 10 (4%) 20 (5%) 0 0.344
Cardiac arrest requiring CPR, n (%) 19 (3%) 3 (1%) 15 (3%) 1 (2%) 0.173
Intra- or postoperative bleeding or
transfusion, n (%)
154 (21%) 26 (10%) 112 (26%) 16 (38%) <0.001
DVT requiring therapy, n (%) 22 (3%) 3 (1%) 16 (4%) 3 (7%) 0.009
Sepsis, n (%) 119 (16%) 29 (11%) 81 (18%) 9 (21%) 0.018
Septic shock, n (%) 61 (8%) 13 (5%) 43 (10%) 5 (12%) 0.046
At least one surgery complication, n (%) 402 (54%) 109 (41%) 264 (60%) 29 (69%) <0.001
30-day mortality, n (%) 61 (8%) 17 (6%) 36 (8%) 8 (19%) 0.021
ASA, American Society of Anesthesiologists; BMI, body mass index; CPR, cardiopulmonary resuscitation; DM, diabetes mellitus; DVT, deep vein
thrombosis; SSI, surgical site infection.
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treatment of hilar cholangiocarcinoma.14 Its search criteria
obtained 24 articles that referred to a total of 2457 patients,
669 (27.2%) of whom underwent vascular resection. The
meta-analysis showed no significant difference in morbidity
between the two groups. With reference to mortality rates, the
authors found significantly higher mortality among patients
undergoing vascular resection (odds ratio 2.07, 95% confidence
interval 1.21–3.57; P = 0.008).14 Another recent meta-analysis
included 13 studies with a total of 1921 patients with hilar
cholangiocarcinoma, of whom 458 were submitted to vascular
resection.15 No significant differences in postoperative
morbidity or mortality were found between the non-vascular
resection and vascular resection groups.
It is interesting to note that the mortality rate of 6.4% in
patients undergoing BEA alone in the current analysis appears
to be higher than equivalent rates reported in the literature.
One explanation may refer to the fact that the NSQIP database
does not indicate whether an operation for cancer is performed
with curative or palliative intent; no designation of resection
status is given. As BEA is the CPT code used as a surrogate for
bile duct resection, it is possible that some patients in the
study cohort may not have undergone curative resections, but,
rather, palliative bypasses for obstructive jaundice in the setting
of unresectable disease. Jarnagin and colleagues at Memorial
Sloan–Kettering Cancer Center reported a postoperative
mortality rate of 11% in patients undergoing palliative biliary-
enteric bypass in the context of unresectable hilar cholangio-
carcinoma or gallbladder carcinoma.28
Multivariate analyses demonstrated preoperative total biliru-
bin, BEA with hepatic resection, and BEA with hepatic and
Table 2 Univariate and multivariate predictors using logistic regression of 30-day morbidity in patients submitted to biliary-enteric
anastomosis (BEA) with and without hepatic or vascular resection
Univariate models Multivariate modela
OR 95% CI P-value OR 95% CI P-value
Ageb 0.99 0.98–1.01 0.356
BMI 1.01 0.98–1.03 0.539
Operation timec 1.02 1.01–1.03 0.003 1.01 1.00–1.02 0.234
Preoperative serum albumin 0.68 0.54–0.84 0.005 0.78 0.60–1.02 0.072
Preoperative total bilirubin 1.09 1.03–1.16 0.002 1.07 1.00–1.14 0.041
Female sex 1.05 0.79–1.41 0.723
Current smoking 1.09 0.74–1.61 0.655
Loss of >10% body weight in last 6 months 1.55 1.03–2.34 0.038 1.44 0.91–2.28 0.125
ASA class 3 or 4 status 1.46 1.05–2.03 0.026 1.27 0.88–1.85 0.207
Independent functional status 0.22 0.66–0.08 0.007 0.71 0.32–1.56 0.389
Diabetes 1.24 0.85–1.81 0.261
Ascites 4.00 1.34–11.92 0.013 2.28 0.71–7.31 0.167
Group
BEA only Ref
BEA with hepatic resection 2.17 1.59–2.96 <0.001 2.84 1.95–4.12 <0.001
BEA with hepatic and vascular resection 3.21 1.60–6.46 0.001 4.38 1.98–9.68 0.003
a
Variables with P-values of <0.1 were selected for the multivariate model.
b
Per 10-year increase.
c
Per 10-min increase.
95% CI, 95% confidence interval; ASA, American Society of Anesthesiologists; BMI, body mass index; OR, odds ratio.
Table 3 Observed and expected (O/E) ratios overall and by group in patients submitted to biliary-enteric anastomosis (BEA) with and
without hepatic or vascular resection
All patients (n = 747) Group 1: BEA only
(n = 266)
Group 2: BEA with
hepatic resection
(n = 439)
Group 3: BEA with
hepatic and vascular
resection (n = 42)
O/E index 95% CI O/E index 95% CI O/E index 95% CI O/E index 95% CI
Morbidity 1.52 1.38–1.68 1.20 0.98–1.45 1.71 1.51–1.93 1.92 1.29–2.76
Mortality 2.03 1.55–2.61 1.44 0.84–2.30 2.16 1.51–2.98 5.92 2.54–11.66
95% CI, 95% confidence interval.
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vascular resection to be independently associated with morbid-
ity. The addition of hepatic and vascular resection was signifi-
cantly correlated with increased postoperative morbidity. The
multivariate analysis of mortality showed age, return to the
operating room, pneumonia, unplanned intubation, progressive
renal insufficiency, acute renal failure, cardiac arrest requiring
CPR, septic shock, and BEA with hepatic and vascular resec-
tion to be significant predictors. The performance of hepatic
resection alone with BEA did not correlate with increased
postoperative mortality.
The O/E ratios in Groups 2 and 3 for postoperative 30-day
morbidity and mortality suggest these outcomes can be
improved. Recent studies have reported that 90-day postopera-
tive outcomes after hepatobiliary procedures represent optimal
measures of surgical quality and that 30-day outcomes are
likely to underestimate postoperative occurrences for patients
in this specific subset.29,30 This is a limitation of the NSQIP
database, although it has been shown that hospitals participat-
ing in the NSQIP have been able to significantly improve their
risk-adjusted complication and mortality rates by making
interventions based on analysis of their 30-day outcomes.31
Although true rates of postoperative morbidity and mortality
for patients in this analysis may be higher, the data presented
here clearly demonstrate significant differences between proce-
dure groups in 30-day outcomes, which potentially can be
improved.
The structure of the NSQIP database precludes any highly
detailed examination of the clinical information as a result of
Table 4 Univariate and multivariate predictors using logistic regression of 30-day mortality in patients submitted to biliary-enteric
anastomosis (BEA) with and without hepatic and vascular resection
Univariate models Multivariate modelsa
OR 95% CI P-value OR 95% CI P-value
Ageb 1.04 1.01–1.06 0.008 1.06 1.02–1.10 0.003
BMI 1.04 1.00–1.08 0.062 1.05 0.99–1.11 0.079
Preoperative serum albumin 0.41 0.28–0.61 <0.001 1.01 0.94–1.09 0.729
Preoperative total bilirubin 1.14 1.06–1.22 0.005 0.98 0.90–1.07 0.627
Female sex 0.68 0.39–1.18 0.168
Current smoking 0.63 0.28–1.42 0.266
Independent functional status 0.32 0.12–0.89 0.028 0.97 0.18–5.17 0.972
ASA class 3 or 4 status 3.36 1.42–7.94 0.006 1.84 0.59–5.72 0.293
Operation timec 1.00 1.00–1.00 0.864
Return to operating room 5.09 2.77–9.34 <0.001 3.06 1.05–8.90 0.040
Deep incisional SSI 0.48 0.06–3.6 0.477
Organ space SSI 2.06 1.15–3.69 0.016 1.18 0.40–3.46 0.762
Pneumonia 2.34 1.00–5.51 0.051 0.04 0.01–0.22 0.003
Unplanned intubation 19.78 10.70–36.57 <0.001 10.23 3.09–33.90 0.001
Pulmonary embolism 2.87 0.60–13.84 0.188
Progressive renal insufficiency 7.82 3.10–19.69 <0.001 16.23 3.53–74.61 0.003
Acute renal failure 30.69 11.17–84.32 <0.001 20.81 4.13–104.85 0.002
Cardiac arrest requiring CPR 80.95 22.75–288.09 <0.001 35.84 5.62–228.76 0.002
Intra- or postoperative bleeding or transfusion 1.55 0.86–2.79 0.147
DVT requiring therapy 1.13 0.26–4.95 0.872
Sepsis 0.66 0.30–1.50 0.324
Septic shock 15.23 8.26–28.07 <0.001 11.44 3.79–34.52 <0.001
Group
BEA only Ref
BEA with hepatic resection 1.31 0.72–2.38 0.378 0.937 0.39–2.24 0.884
BEA with hepatic and vascular resection 3.45 1.38–8.59 0.008 5.255 1.43–19.33 0.013
a
Variables with P-values of <0.1.
b
Per 10-year increase.
c
Per 10-min increase.
95% CI, 95% confidence interval; ASA, American Society of Anesthesiologists; BMI, body mass index; CPR, cardiopulmonary resuscitation; DVT,
deep vein thrombosis; OR, odds ratio; SSI, surgical site infection.
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the standardized nature of data collection and efforts to
protect patient privacy. A report by Loehrer and colleagues at
Indiana University used the NSQIP database to examine out-
comes in cholangiocarcinoma and mentioned the lack of
hepatobiliary-specific variables that might provide greater
clinical insight and risk adjustment for patients with hepato-
biliary and gallbladder carcinomas.32 However, the current
analysis does bring up topics for discussion that may guide
future efforts to improve outcomes. Over 30% of deaths in all
procedure groups were associated with pulmonary complica-
tions. The use of preoperative pulmonary rehabilitation and
optimization, as well as evidence-based respiratory care path-
ways in the perioperative period may help to prevent patients
from requiring extended time on ventilator support. Septic
shock was also associated with mortality, and patients with
biliary involvement by tumour can often develop cholangitis
as a result of biliary obstruction. The multivariate morbidity
analysis showed the total bilirubin level to be significant and
indicated that the role of preoperative biliary drainage needs
to be better defined. The increased rate of acute renal failure
seen in the Group 3 patient deaths may reflect the end-stage
result of fulminant postoperative hepatic failure with con-
comitant hepatorenal syndrome. The inclusion of data on the
future liver remnant, the use of portal vein embolization, and
postoperative liver function laboratory values would be extre-
mely helpful in analyses of outcomes in these patients in
future research studies.
Conclusions
This large database analysis clearly demonstrates that when
hepatectomy and vascular resection are performed in conjunc-
tion with bile duct resection for malignancy, 30-day postopera-
tive outcomes are significantly worse than those in patients
submitted to bile duct resection alone. The performance of
hepatectomy, or hepatectomy and vascular resection with BEA
correlated with increased morbidity, whereas only combined
hepatectomy and vascular resection was a significant predictor
of mortality. More than a third of all deaths in each procedure
group were associated with pulmonary complications and sep-
tic shock. The high O/E ratios in patients undergoing BEA and
hepatectomy, as well as BEA with combined hepatectomy and
vascular resection suggest these outcomes can be improved.
The current results support further efforts to clearly define the
specific drivers of these outcomes so that appropriate interven-
tions can be performed.
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